Clinical Trials Logo

Filter by:
NCT ID: NCT06075537 Enrolling by invitation - Clinical trials for Mucopolysaccharidosis II

An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Start date: September 20, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This is a multiregional open-label extension (OLE) to assess the safety, tolerability, and efficacy of long-term treatment with tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant intravenous (IV) enzyme replacement therapy (ERT) for Hunter syndrome (MPS II). Participants who complete at least through the Week 49 visit in Study DNLI-E-0002 and do not discontinue study intervention early and participants who complete Study DNLI-E-0007 will be enrolled in this OLE. All participants will receive DNL310 for up to 5 years from the time of entry in this OLE. Participants, site staff, and the Sponsor will remain blinded to the original treatment assignment for participants entering this OLE from Study DNLI-E-0007.

NCT ID: NCT06045962 Enrolling by invitation - Ureteral Stent Clinical Trials

Optimal Stent Duration After Ureteroscopy

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine how soon ureteral stents can be safely removed following surgery.

NCT ID: NCT06041906 Enrolling by invitation - Clinical trials for Congenital Porto-Systemic Shunt (CPSS)

International Registry of Congenital Portosystemic Shunt (IRCPSS)

IRCPSS
Start date: April 26, 2018
Phase:
Study type: Observational [Patient Registry]

Congenital Portosystemic Shunt (CPSS) is a rare condition important by the multiplicity and severity of associated complications. CPSS is venous anomaly in which blood coming from the intestines only partially passes through the liver. This leads to the accumulation of potentially toxic factors that cause systemic effects. Complications vary among the individuals, and currently, it is challenging to predict which individuals will develop severe complications. The IRCPSS registry is established with the aim of centralizing detailed clinical follow-up and biological information from participants around the world who suffer from Congenital Portosystemic Shunt (CPSS). A multidisciplinary consortium of experts is collaborating to enhance our understanding of the prevalence, natural history, individual risks, and physiopathology of the disease through the IRCPSS registry.

NCT ID: NCT06035562 Enrolling by invitation - Anhedonia Clinical Trials

Promoting Positive Emotional Functioning in Police and Military Populations

Start date: September 5, 2023
Phase: N/A
Study type: Interventional

This study will examine whether actively serving and veteran members of the Canadian Armed Forces (CAF) and Royal Canadian Mounted Police (RCMP) who complete a treatment targeting anhedonia symptoms and amplifying positive emotional processing: 1) experience significant symptom reductions in anxiety, trauma, and depressive symptoms; 2) report increased experience of positive emotions; 3) report improvements to broad functioning and quality of life; and 4) find the treatment to be highly tolerable.

NCT ID: NCT06034821 Enrolling by invitation - Clinical trials for Acute Suicidal Depression (ASD)

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan

REaKT-SD
Start date: October 1, 2023
Phase: Phase 4
Study type: Interventional

This study is a randomized open-label single-blind non-inferiority comparative effectiveness study of ECT vs. KET for the treatment of Acute Suicidal Depression (ASD).

NCT ID: NCT06033274 Enrolling by invitation - Clinical trials for Tricuspid Regurgitation

Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment

TRIPLACE
Start date: October 5, 2023
Phase:
Study type: Observational

The field of transcatheter tricuspid valve replacement (TTVR) is rapidly emerging and data on this topic are scarce. Particularly, little is known about which patients are at greatest risk of procedural complications, such as the timing and onset of conduction disturbances necessitating permanent pacemaker implantation, and how such patients are managed. On this background, the TRIPLACE Registry - an investigator-initiated global multicenter registry - is aimed at better understanding the safety and efficacy of orthotopic TTVR.

NCT ID: NCT06007677 Enrolling by invitation - Clinical trials for Hereditary Angioedema

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

Start date: September 26, 2023
Phase: Phase 2
Study type: Interventional

The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.

NCT ID: NCT05980949 Enrolling by invitation - Clinical trials for Psychosis Associated With Alzheimer's Disease

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease

ADEPT-3
Start date: July 11, 2023
Phase: Phase 3
Study type: Interventional

This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026 or CN012-0027. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 or CN012-0027 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.

NCT ID: NCT05952258 Enrolling by invitation - Clinical trials for Stress Urinary Incontinence

Magnetic Stimulation as a Treatment for Stress Urinary Incontinence

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to determine the efficacy of electromagnetic stimulation treatment of the pelvic floor muscles in adult females with stress urinary incontinence.

NCT ID: NCT05897957 Enrolling by invitation - Parkinson Disease Clinical Trials

Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01

Start date: May 16, 2023
Phase:
Study type: Observational

This is a multicenter study to evaluate the safety and clinical outcomes of BRT-DA01 in subjects with PD who previously received BRT-DA01 in the Phase 1 Study MSK-DA01-101.No investigational therapy will be administered in this study.